Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 4Leukemia 2Anemia, Refractory, with Excess of Blasts 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Hematologic Neoplasms 1Hematologic Diseases 1GATA2 Deficiency 1Frailty 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 2umbralisib 1ublituximab 1prednylidene 1fludarabine phosphate 1epratuzumab 1deltacortene 1cc-486 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Specimen Handling 1Rituximab 1Radioimmunodetection 1Prednisone 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Etoposide 1Doxorubicin 1Carboplatin 1CT-P10 1Busulfan 1Bendamustine Hydrochloride 1Azacitidine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, B-Cell, Marginal Zone × Azacitidine × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡